Increased vascular wall thrombogenicity combined with reduced blood flow promotes occlusive thrombus formation in rabbit femoral artery

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 24, Issue 12, 2004, Pages 2420-2424

  Yamashita, Atsushi ^a   Furukoji, Eiji ^a   Marutsuka, Kousuke ^a   Hatakeyama, Kinta ^a   Yamamoto, Hiroshi ^b   Tamura, Shozo ^a   Ikeda, Yasuo ^c   Sumiyoshi, Akinobu ^a   Asada, Yujiro ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b AJINOMOTO CO INC   (Japan)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Blood flow; Thrombus propagation; Tissue factor; Von Willebrand factor

Indexed keywords

MONOCLONAL ANTIBODY; THROMBOPLASTIN; VON WILLEBRAND FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY THROMBOSIS; ARTICLE; BLOOD FLOW VELOCITY; CONTROLLED STUDY; FEMORAL ARTERY FLOW; MALE; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RABBIT; THROMBOGENESIS; THROMBOGENICITY; THROMBOSIS PREVENTION;

ANIMALS; ARTERIAL OCCLUSIVE DISEASES; BALLOON DILATATION; CONNECTIVE TISSUE; CONSTRICTION, PATHOLOGIC; DISEASE MODELS, ANIMAL; FEMORAL ARTERY; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; NEOVASCULARIZATION, PATHOLOGIC; RABBITS; REGIONAL BLOOD FLOW; THROMBOPLASTIN; THROMBOSIS; TUNICA INTIMA;

EID: 10644234022     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000147767.61336.de     Document Type: Article

References (36)

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992;326:242-250.
2. Gutstein DE, Fuster V. Pathophysiology and clinical significance of atherosclerotic plaque rupture. Cardiovasc Res. 1999;41:323-333.
3. Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med. 1984;310:1137-1140.
4. Arbustini E, Grasso M, Diegoli M, Morbini P, Aguzzi A, Fasani R, Specchia G. Coronary thrombosis in non-cardiac death. Coron Artery Dis. 1993;4:751-759.
5. Davies MJ. Stability and instability: Two faces of coronary atherosclerosis. Circulation. 1996;94:2013-2020.
6. Ruggeri ZM. Perspective series: Cell adhesion in vascular biology, von Willebrand factor. J Clin Invest. 1997;99:559-564.
7. Goto S, Ikeda Y, Saldivar E, Ruggeri ZM. Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions. J Clin Invest. 1998;101:479-486.
8. Kulkarni S, Dopheide SM, Yap CL, Ravanat C, Freund M, Mangin P, Heel KA, Street A, Harper IS, Lanza F, Jackson SP. A revised model of platelet aggregation. J Clin Invest. 2000;105:783-791.
9. Badimon JJ, Lettino M, Toschi V, Fuster V, Berrozpe M, Chesebro JH, Badimon L. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation. 1999;99:1780-1787.
10. Yamashita A, Asada Y, Sugimura H, Yamamoto H, Marutsuka K, Hatakeyama K, Tamura S, Ikeda Y, Sumiyoshi A. Contribution of von Willebrand Factor in thrombus formation on neointima of rabbit stenotic iliac artery under high blood flow velocity. Arterioscler Thromb Vasc Biol. 2003;23:1105-1110.
11. Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation. 2000;101:570-580.
12. Skyschally A, Erbel R, Heusch G. Coronary microembolization. Circ J. 2003;67:279-286.
13. Kageyama S, Yamamoto H, Nagano M, Arisaka H, Kayahara T, Yoshimoto R. Anti-thrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factor. Br J Pharmacol. 1997;122:165-171.
14. Kageyama S, Yamamoto H, Nakazawa H, Matsushita J, Kouyama T, Gonsho A, Ikeda Y, Yoshimoto R. Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkeys. Arterioscler Thromb Vasc Biol. 2002;22:187-192.
15. Kurokawa T, Iwasa S, Kakinuma A, Stassen JM, Lijnen HR, Collen D. Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator. Thromb Haemost. 1991;66:684-693.
16. Asada Y, Hara S, Tsuneyoshi A, Hatakeyama K, Kisanuki A, Marutsuka K, Sato Y, Kamikubo Y, Sumiyoshi A. Fibrin-rich and platelet rich thrombus formation on neointima: Recombinant tissue factor pathway inhibitor prevents fibrin formation and neointimal development following repeated balloon injury of rabbit aorta. Thromb Haemost. 1998;80:506-511.
17. Atsuchi N, Nishida T, Marutsuka K, Asada Y, Kamikubo Y, Takeshita A, Ueno H. Combination of a brief irrigation with tissue factor pathway inhibitor (TFPI) and adenovirus-mediated local TFPI gene transfer additively reduces neointima formation in balloon-Injured rabbit carotid arteries. Circulation. 2001;103:570-575.
18. Groves HM, Kinlough-Rathbone RL, Richardson M, Jorgensen L, Moore S, Mustere JF. Thrombin generation and fibrin formation following injury to rabbit neointima. Studies of vessel wall reactivity and platelet survival. Lab Invest. 1982;46:605-612.
19. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation. 1985;71:699-708.
20. Davies MJ, Thomas AC, Knapman PA, Hangartner JR. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation. 1986;73:418-427.
21. Frink RJ, Rooney PA, Trowbridge JO, Rose JP. Coronary thrombosis and platelet/fibrin microemboli in death associated with acute myocardial Infarction. Br Heart J. 1988;59:196-200.
22. Taylor AJ, Bobik A, Berndt MC, Ramsay D, Jennings G. Experimental rupture of atherosclerotic lesions increases distal vascular resistance. A limiting factor to the success of infarct angioplasty. Arterioscler Thromb Vasc Biol. 2002;22:153-160.
23. West JW, Kobayashi T, Anderson FS. Effects of selective coronary embolization on coronary blood flow and coronary sinus venous blood oxygen saturation in dogs. Circ Res. 1962;10:722-738.
24. Bonderman D, Teml A, Jakowitsch J, Adlbrecht C, Gyongyosi M, Sperker W, Lass H, Mosgoeller W, Glogar DH, Probst P, Maurer G, Nemerson Y, Lang IM. Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. Blood. 2002;99:2794-2800.
25. Marzilli M, Sambuceti G, Fedele S, L'Abbate A. Coronary microcirculatory vasoconstriction during ischemia in patients with unstable angina. J Am Coll Cardiol. 2000;35:327-334.
26. Erbel R, Heusch G. Coronary microembolization. J Am Coll Cardiol. 2000;36:22-24.
27. Rentrop KP. Thrombi in acute coronary syndromes. Revisited and revised. Circulation. 2000;101:1619-1626.
28. Gemmell CH, Turitto VT, Nemerson Y. Flow as a regulator of the activation of factor X by tissue factor. Blood. 1988;72:1404-1406.
29. Loscalzo J, Inbal A, Handin RI. von Willebrand protein facilitates platelet incorporation in polymerizing fibrin. J Clin Invest. 1986;78:1112-1119.
30. Endenburg SC, Hantgan RR, Lindeboom-Blokzijl L, Lankhof H, Jerome WG, Lewis JC, Sixma JJ, de Groot PG. On the role of von Willebrand factor in promoting platelet adhesion to fibrin in flowing blood. Blood. 1995;86:4158-4165.
31. Andre P, Denis CV, Ware J, Saffaripour S, Hynes RO, Ruggeri ZM, Wagner DD. Platelets adhere to and translocate on von Willebrand factor presented by endothelium in stimulated veins. Blood. 2000;96:3322-3328.
32. Methia N, Andre P, Denis CV, Economopoulos M, Wagner DD. Localized reduction of atherosclerosis in von Willebrand factor-deficient mice. Blood. 2001;98:1424-1428.
33. Himber J, Kling D, Fallon JT, Nemerson Y, Riederer MA. In situ localization of tissue factor in human thrombi. Blood. 2002;99:4249-4250.
34. Rauch U, Bonderman D, Bohrmann B, Badimon JJ, Himber J, Riederer MA, Nemerson Y. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood. 2000;96:170-175.
35. Muller I, Klocke A, Alex M, Kotzsch M, Luther T, Morgenstern E, Zieseniss S, Zahler S, Preissner K, Engelmann B. Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets. FASEB J. 2003;17:476-478.
36. Camera M, Frigerio M, Toschi V, Brambilla M, Rossi F, Cottell DC, Maderna P, Parolari A, Bonzi R, De Vincenti O, Tremoli E. Platelet activation induces cell-surface immunoreactive tissue factor expression, which is modulated differently by antiplatelet drugs. Arterioscler Thromb Vasc Biol. 2003;23:1690-1696.